What happened
Samsung Biologics disclosed a supply contract, worth US$69.6M, about 2.05% of its recent annual revenue, running through Dec 2031.
For context, this single contract equals about 2.05% of the company's most recent annual revenue.
| Counterparty | Disclosed |
|---|---|
| Contract value | US$69.6M |
| vs. recent revenue | 2.05% |
| Through | Dec 2031 (from Oct 2026) |
| Filed | 2026-10-02, Supply contract signed (voluntary) |
| Source | DART rcept 20261002800830 → open original filing |
Source: DART. Information only, not investment advice.